Results 21 to 30 of about 13,617 (225)

High‐dose non‐sedating antihistamines are used insufficiently in chronic urticaria patients treated with omalizumab

Clinical and Translational Allergy, 2021
Background The lifetime prevalence of chronic urticaria (CU) is 0.5%–1%. In some patients with CU, symptomatic control is not achieved with non‐sedating second‐generation H1 antihistamines (nsAH1) alone, even with quadrupled standard doses as recommended
Hanne Madsen, Charlotte G. Mortz, Carsten Bindslev‐Jensen, Mette Reilev, Jesper Hallas, Daniel P. Henriksen   +5 more
doaj   +1 more source

PK/PD modeling to characterize placebo and treatment effect of omalizumab for chronic spontaneous urticaria

CPT: Pharmacometrics & Systems Pharmacology, 2023
The pharmacokinetic (PK) characteristics of omalizumab and its pharmacodynamic (PD) effect in patients has yet to be fully characterized in chronic spontaneous urticaria, which could elucidate its pathogenesis and treatment response.
Elise Oh, Russ Wada, Kha Le, Yanan Zheng, Jin Jin, Victor Poon, Kit Wong, Ryan Owen, Kenta Yoshida   +8 more
doaj   +1 more source

Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. [PDF]

, 2021
Bullous pemphigoid (BP) is a blistering autoimmune skin disease. Omalizumab, a monoclonal antibody directed to IgE, showed a beneficial effect in treatment of recalcitrant BP in case series.
Bossart, Simon, Schlapbach, Christoph, Borradori, Luca, Feldmeyer, Laurence, Seyed Jafari, S. Morteza, Simon, Dagmar   +5 more
core   +1 more source

Severe pediatric asthma with a poor response to omalizumab: a report of three cases and three-dimensional bronchial wall analysis

Journal of International Medical Research, 2022
Omalizumab is used for the treatment of persistent severe allergic asthma in adults and children. However, some patients remain symptomatic even after omalizumab treatment. In bronchial asthma, chronic inflammation of the bronchial wall causes thickening
Mitsuru Tsuge, Masanori Ikeda, Yoichi Kondo, Hirokazu Tsukahara   +3 more
doaj   +1 more source

Long-term effectiveness and safety of omalizumab in pediatric and adult patients with moderate-to-severe inadequately controlled allergic asthma

World Allergy Organization Journal, 2022
Omalizumab is recommended as an add-on therapy in patients aged ≥6 years with inadequately controlled, moderate-to-severe persistent allergic asthma. The efficacy and safety of omalizumab treatment in allergic asthma clinical trials and its effectiveness
Nicola A. Hanania, MD, Robert Niven, MD, Pascal Chanez, MD, PhD, Deschildre Antoine, MD, PhD, Pascal Pfister, MD, Lorena Garcia Conde, MD, Xavier Jaumont, MD   +6 more
doaj   +1 more source

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange. [PDF]

, 2016
Omalizumab is a widely used therapeutic anti-IgE antibody. Here we report the crystal structure of the omalizumab-Fab in complex with an IgE-Fc fragment. This structure reveals the mechanism of omalizumab-mediated inhibition of IgE interactions with both
Graham, Michelle T, Tarchevskaya, Svetlana, Nadeau, Kari Christine, Jardetzky, Theodore S, Brigger, Daniel, Sathiyamoorthy, Karthik, Pennington, Luke F, Eggel, Alexander   +7 more
core   +1 more source

Learnings from real-life experience of using omalizumab for chronic urticaria in Latin America

World Allergy Organization Journal, 2019
Background: Updated urticaria guidelines recommend that patients should be assessed for disease activity, severity, control, and quality of life at baseline and follow up.
Ivan Cherrez-Ojeda, Marcus Maurer, Jonathan A. Bernstein, Emanuel Vanegas, Miguel Felix, German D. Ramon, Luis Felipe Ensina, José Ignacio Larco Sousa, Edgar Emilio Matos Benavides, R. Cardona Villa, P. Latour Staffeld, Blanca María Morfin-Maciel, Jose Mori, Paul Wilches C, Valeria L. Mata, Annia Cherrez   +15 more
doaj   +1 more source

Cost-effectiveness of omalizumab in real world uncontrolled allergic asthma patients

Pulmonology, 2021
Objective To estimate the cost-effectiveness of omalizumab compared with standard of care in the treatment and control of severe persistent asthma, using the outcomes from the Portuguese subpopulation of the eXpeRience registry.Methods This was a ...
A. Arrobas, M.P. Barbosa, S. Rabiais, B. Vandewalle, J. Félix   +4 more
doaj   +3 more sources

Description of Baseline Characteristics of Pediatric Allergic Asthma Patients Including those Initiated on Omalizumab

Allergy & Rhinology, 2018
Background Indication of omalizumab in the United States was recently extended to include pediatric (6–11 years) uncontrolled moderate-to-severe allergic asthma patients.
Abhishek Kavati, Dominic Pilon, Benjamin Ortiz, Brandee Paknis, Ashok Vegesna, Bradd Schiffman, Maryia Zhdanava, Patrick Lefebvre, Brian Stone   +8 more
doaj   +1 more source

Development of Assay for Determining Free IgE Levels in Serum from Patients Treated with Omalizumab

Allergology International, 2014
Background: Omalizumab, a monoclonal anti-IgE antibody, is currently indicated for the treatment of moderate-to-severe allergic asthma. To measure active IgE levels in sera from patients treated with omalizumab, the IgE subfraction in complex with ...
Reiko Ito, Yasuhiro Gon, Satoshi Nunomura, Ryo Atsuta, Norihiro Harada, Tomohiro Hattori, Shuichiro Maruoka, Yoshimichi Okayama, Chisei Ra, Shu Hashimoto   +9 more
doaj   +1 more source